Catalysts · GSK · CIK 1131399 · page 4 of 4

GSK catalysts and FDA events, page 4.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on GSK PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
April 22, 2021Jemperli (dostarlimab-gxly)GSKFDA approval—ApprovedopenFDA Drugs@FDA
March 1, 2021Dovato (dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
March 1, 2021Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
January 21, 2021Cabenuva Kit (cabotegravir; rilpivirine)GSKFDA approval—ApprovedopenFDA Drugs@FDA
January 21, 2021Vocabria (cabotegravir sodium)GSKFDA approval—ApprovedopenFDA Drugs@FDA
December 16, 2020Benlysta (belimumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
October 30, 2020Selzentry (maraviroc)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
September 25, 2020Nucala (mepolizumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
September 9, 2020Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
August 6, 2020Dovato (dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
July 14, 2020Juluca (dolutegravir sodium; rilpivirine hydrochloride)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
July 2, 2020Rukobia (fostemsavir tromethamine)GSKFDA approval—ApprovedopenFDA Drugs@FDA
June 12, 2020Tivicay (dolutegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
June 12, 2020Tivicay (dolutegravir sodium)GSKFDA approval—ApprovedopenFDA Drugs@FDA
April 29, 2020ZEJULA (niraparib)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
December 19, 2019Cabenuva Kit (cabotegravir; rilpivirine)GSKComplete Response Letter—CRL issuedFDA Complete Response Letters
December 19, 2019Vocabria (cabotegravir sodium)GSKComplete Response Letter—CRL issuedFDA Complete Response Letters
June 6, 2019Nucala (mepolizumab)GSKFDA approval—ApprovedopenFDA Drugs@FDA
April 8, 2019Dovato (dolutegravir sodium; lamivudine)GSKFDA approval—ApprovedopenFDA Drugs@FDA
July 20, 2018ARAKODA® (tafenoquine)GSKFDA approval—ApprovedopenFDA Drugs@FDA
November 21, 2017Juluca (dolutegravir sodium; rilpivirine hydrochloride)GSKFDA approval—ApprovedopenFDA Drugs@FDA
September 18, 2017Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate)GSKFDA approval—ApprovedopenFDA Drugs@FDA
July 20, 2017Benlysta (belimumab)GSKFDA approval—ApprovedopenFDA Drugs@FDA
March 27, 2017ZEJULA (niraparib)GSKFDA approval—ApprovedopenFDA Drugs@FDA
November 4, 2016Selzentry (maraviroc)GSKFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from GSK’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.